LL-37 vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 47% LL-37 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
LL-37 Tesamorelin
Weight — 5,135.9 Da
Half-life Short (rapid proteolytic degradation) 26-38 minutes
Chain 37 amino acids 44 amino acids
Type Cationic antimicrobial peptide GHRH analog
Key Benefits
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
LL-37 Tesamorelin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.